Aclaris reports positive Phase 1b results for anti-TSLP bispecific ATI-052
Aclaris Therapeutics announced rapid and robust responses to its bispecific antibody ATI-052 in atopic dermatitis and asthma trials, with a favorable safety profile, strong clinical proof-of-concept, and plans to advance the candidate into Phase 2b development for eosinophilic esophagitis.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed